Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$105.04
▼ $1.95 (-1.8%)
Market data updated: 09/20 04:52 AM
News analyzed: 09/20/2026
Market Cap
$8.25B
Day Range
$103.89 - $107.19
52-Week Range
$69.81 - $148.83
Beta
—
Next Earnings
21.09.2026
Support
$101.29
Resistance
$141.00
ABVX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+26.1% (1Y)
🔴 Weak
Strengths: 2/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Calmar Ratio (return vs. drawdown)
Calmar: 2.06 (3y annualized return 139.0% / max drawdown 67.5%)
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 4.6% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
39
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
23
Risk
50
Sentiment
74
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Abivax SA** has focused on its **Obefazimod**, a late-stage drug candidate for **ulcerative colitis**, highlighted alongside other emerging therapies in the expanding treatment landscape for moderate-to-severe disease. The company also saw **institutional investor activity** and **technical trading interest**, including upgrades to its stock rating and discussions in healthcare investment funds. Additionally, Abivax’s **board strengthened with a new pharmaceutical executive**, though no direct Abivax-related updates were provided beyond these themes.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Abivax SA. News trend score: 74. Reason: 8 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
50
Psychology
69
Fundamentals
—
Technical
23
Valuation
—
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+6%
Market Narrative
45
Fundamental Reality
50
Narrative Gap
-5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ABVX’s psychology is fragmented, with no dominant state but anchoring (20) as the highest single signal. The 4% distance above support may be reinforcing a mental reference point, while mixed signals—like positive sentiment (86/100) and negative momentum—suggest traders are torn between cautious optimism and technical caution. The narrative gap (3) hints at a slight disconnect between market perception and fundamentals, but the lack of extreme volatility or panic signals keeps behavior balanced. The key question: will traders hold the anchor or react to momentum shifts?
Updated: 09/08/2026, 03:42 PM
What could change this?
👥 What the crowd believes
"Obefazimod (Abivax) among emerging therapies for ulcerative colitis"
"Whale alerts tracking transactions for Abivax (ABVX)"
"ABVX shows strong breakout setup with 9/10 technical ratings"
📈 18D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 95/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on his documented principles, the model estimates that Samuel Armstrong Nelson would view ABVX as being in a relatively favorable cycle position, nearer the oversold side than overbought, giving a high score of 97. Charles Mackay’s framework, which looks for crowd‑maniac behaviour, finds no obvious signs of excessive optimism, leading to a solid but lower score of 78. Howard Marks’ cycle‑aware approach places the stock somewhere in the middle of the overall market cycle (score 60), while his more fundamentals‑focused view notes mixed signals—a good business but already high expectations (score 56). Investors such as Gerald Loeb and Burton Malkiel/Bogle see heightened risk and weak fundamentals, assigning scores of 31 and 30 respectively, whereas more trend‑oriented readers like Jesse Livermore and Morgan Housel give low scores of 15 and 0 because the stock’s recent trend runs against Livermore’s rule and its volatility could shake out patient holders. Overall, the range of scores reflects a split between cyclical optimism and caution about risk, growth and volatility.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 67
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 65
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 63
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 31
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 29
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 19
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 8 positive, 8 neutral, 4 negative out of the last 20 articles.
SeekingAlpha · 19.9.2026
Yahoo · 18.9.2026
Benzinga · 16.9.2026
Benzinga · 14.9.2026
GuruFocus.com · 11.9.2026
MT Newswires · 10.9.2026
Benzinga · 10.9.2026
Benzinga · 10.9.2026
Yahoo · 8.9.2026
Zacks · 8.9.2026
Yahoo · 7.9.2026
GlobeNewswire · 7.9.2026
GlobeNewswire · 1.9.2026
Benzinga · 27.8.2026
Benzinga · 18.8.2026
Benzinga · 12.8.2026
ChartMill · 11.8.2026
SeekingAlpha · 7.8.2026
Business Wire · 4.8.2026
Yahoo · 4.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Abivax SA (ABVX) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for ABVX specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
ABVX's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Calmar: 2.06 (3y annualized return 139.0% / max drawdown 67.5%); +3.9% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: ATR: 4.6% of price; Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for ABVX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
6,962,029 shares short as of 2026-08-31 · vs. 5,194,797 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
43.2% of trading volume this week was short selling, vs. 39.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology